CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit for the first three quarters was approximately RMB1.307 billion, a year-on-year decrease of 6.51%.
China Resources Pharmaceutical (03320) announced the first three quarters of 2026 results for China Resources Double-Crane Pharmaceutical, with total operating revenue of approximately RMB8.066 billion, a year-on-year decrease of 4%; net profit of approximately RMB1.307 billion, a year-on-year decrease of 6.51%.
CHINARES PHARMA (03320) announced the results of China Resources Double-Crane Pharmaceutical for the first three quarters of 2026: total operating revenue was approximately RMB8.066 billion, a year-on-year decrease of 4%; net profit was approximately RMB1.307 billion, a year-on-year decrease of 6.51%.
Related Articles
MING YUAN CLOUD (00909) repurchased 500,000 shares on October 27 for HK$364,100.
Techtronic Industries (00669) repurchased 82,500 shares on October 27 for HK$10.7376 million.
WEIGAO GROUP (01066) repurchased 80,000 shares for HK$260,200 on October 27.
MING YUAN CLOUD (00909) repurchased 500,000 shares on October 27 for HK$364,100.
Techtronic Industries (00669) repurchased 82,500 shares on October 27 for HK$10.7376 million.
WEIGAO GROUP (01066) repurchased 80,000 shares for HK$260,200 on October 27.
